Search Results

• • 3 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance

  Authors:Joseph B. Sempa, Alex Welte, Michael P. Busch, Jake Hall, Dylan Hampton, Shelley N. Facente, et al.From:PLoS ONE (Vol. 14, Issue 7) Peer-Reviewed

  July 26, 20197,040 words Report 1570LBackground Two manufacturers, Maxim Biomedical and Sedia Biosciences Corporation, supply CDC-approved versions of the HIV-1 Limiting Antigen Avidity EIA (LAg) for detecting 'recent' HIV infection in cross-sectional...

• HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication

  Authors:Sheila M. Keating, Christopher D. Pilcher, Vivek Jain, Mila Lebedeva, Dylan Hampton, Mohamed Abdel-Mohsen, et al.From:Journal of Infectious Diseases (Vol. 216, Issue 1) Peer-Reviewed

  July 1, 2017 Article

   Citation Only

• Development of an international external quality assurance program for HIV-1 incidence using the Limiting Antigen Avidity assay

  Authors:Sheila M. Keating, Wes Rountree, Eduard Grebe, Andrea L. Pappas, Mars Stone, Dylan Hampton, et al.From:PLoS ONE (Vol. 14, Issue 9) Peer-Reviewed

  Sept. 16, 20196,749 words Report 1560LLaboratory assays for identifying recent HIV-1 infections are widely used for estimating incidence in cross-sectional population-level surveys in global HIV-1surveillance. Adequate assay and laboratory performance are...